Olipudase Alfa-rpcp (Xenpozyme™)

Covered: Olipudase alfa (Xenpozyme) is authorized for non‑CNS manifestations of ASMD in adults and pediatrics with ASMD type B or A/B (ASMD type A alone and CNS manifestations are excluded). Key requirements: documented enzymatic assay and clinical signs of ASMD, prescription by or consultation with a geneticist/endocrinologist/metabolic/lysosomal disorders specialist, weight‑based IV dosing every 2 weeks with specified escalation to 3 mg/kg (use adjusted body weight if BMI>30), and approval limited to 12 months.

"Xenpozyme is indicated for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients"

Sign up to see full coverage criteria, indications, and limitations.